Pyxis Oncology announced that CEO Tom Civik will participate in fireside chats at the Guggenheim Healthcare Innovation Conference on November 9 and the Stifel Healthcare Conference on November 10, 2026. The company is developing MICVO, a novel cancer treatment targeting difficult-to-treat solid tumors, currently in Phase 1 and Phase 1/2 clinical trials. MICVO has received Fast Track Designation from the FDA for treating recurrent and metastatic head and neck cancer. Live webcasts of the discussions will be available on Pyxis Oncology's investor relations website.
Pyxis Oncology's upcoming investor conference participation is context for readers following healthcare stocks. For readers following healthcare stocks, here is Pluang's market snapshot as of Oct 28, 2026 17:41 WIB: out of 150 priced US health-sector stocks, 42 rose and 94 fell. Notable movers include TWST at USD 163.00 with a 1-day change of +1.97%, MRNA at USD 204.09 with a 1-day change of -1.87%, and IMVT at USD 29.40 with a 1-day change of +1.80%.
Circuit Mind secured $25 million in funding, including an $18.5 million Series A led by Norwest, to expand its AI platform that automates and optimizes electronic circuit board design. The platform helps companies reduce design time by up to 90%, cut...
Circuit Mind has introduced AVE (Agentic Verification Engine), an AI-powered application that verifies printed circuit board (PCB) schematics against datasheets and internal design rules to catch errors early and avoid expensive respins. AVE compleme...
Alvotech, a global biotech company specializing in biosimilars, will release its financial results for the first nine months of 2026 on November 11 after U.S. market close. A live webcast presentation is scheduled for November 12 at noon, where manag...
Sampo Oyj will publish its financial results for the first nine months of 2026 on November 4, 2026, at around 8:30 AM. Alongside the report, supplementary presentation materials will be available on their website. An investor conference call will be ...
Alvotech, a global biotech company specializing in biosimilars, announced it will report its financial results for the nine months and third quarter ending September 30, 2026, on November 11 after U.S. market close. The company will host a webcast wi...
